In 156 patients with RAS/BRAF wild-type metastatic colorectal cancer, adding avelumab to cetuximab rechallenge did not improve overall survival (median 14.8 vs 12.9 months; HR 1.00). Exploratory: tumours without EGFR-pathway variants on liquid biopsy did better.
RCTn = 156
Ciardiello et al. Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial